Advertising Exhibitors Gallery
Advertising Exhibitors Gallery
IIR's Clinical Trials Congress
February 2527, 2008
Loews Royal Pacific Resort, Orlando, FL
ALMAC Clinical Technologies
Booth Number: 408
1040 Stony Hill Road
Suite 200
Yardley, PA 19067
Phone: 267-685-4284
Email: integrated@almacgroup.com
www: www.almacgroup.com
EResearchTechnology, Inc.
Booth Number: 207
30 South 17th Street
Philadelphia, PA 19103
Phone: 215-972-0420
Fax:215-972-0414
Email: eresearch@ert.com
www: www.ert.com
MedNet Solutions, Inc.
Booth Number: 506
601 Carlson Parkway
Suite 605
Minnetonka, MN 55305
Phone: 763-258-2735
Fax: 763-258-2737
Email: info@mednetstudy.com
www: www.mednetstudy.com
United BioSource Corporation
Booth Number: 505
7501 Wisconsin Avenue
Suite 705
Bethesda, MD 20814
Phone: 866-458-1096
Fax: 240-644-0421
Email: info@unitedbiosource.com
www: www.unitedbiosource.com
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.